Page 1,186«..1020..1,1851,1861,1871,188..1,2001,210..»

Novel Dementia Vaccine Could Be the "Breakthrough" of the Decade – Interesting Engineering

Posted: January 9, 2020 at 9:49 am

New research has developed a vaccine designed to prevent the neurodegeneration associated with Alzheimers disease, and researchers hope this will be the "breakthrough of the decade," according to ABC News Australia.The researchers believe that this treatment is now ready for human trials.

RELATED:8 GREAT APPS FOR DEMENTIA AND ALZHEIMER'S PATIENTS AND THEIR FAMILIES

The vaccine is created to produce antibodies that both prevent and remove amyloid and tau proteins in the brain, the accumulation of which is believed to be the main cause of neurodegeneration in Alzheimers disease.

Many previously failed Alzheimers treatments have focused either on amyloid or tau protein reductions, but never both. However, research increasingly suggests it is a synergic relationship between the two toxic proteins that may be responsible for neurodegeneration.

The novel vaccine is actually a combination of two vaccines. AV-1959R targets amyloid aggregations, and AV-1980R targets the tau protein ones.

Nikolai Petrovsky, a scientist from Australias Flinders University and one of the team's researchers, told ABC News Australia the new treatment could be both preventative and curative.

"It's actuallydesigned to be both a prophylactic and a therapeutic," he said.

"In the animal models, we can both use it to prevent the development of memory loss by giving it before the animal starts to get these build-ups of proteins. But we can also show that even when we give it after the animals have proteins, we can actuallyget rid of the abnormal proteins," added the researcher.

Now,Petrovsky hopes human trials can startin the next 18-to-24 months."It's an exciting time to be starting the new decade hopefully this is the breakthrough of the next decade if we can get it to work in the human trials," he said.

The research is being led and funded by the Institute for Molecular Medicine and the University of California, in the US. And we can only hope it ends up being a total success.

Read more:
Novel Dementia Vaccine Could Be the "Breakthrough" of the Decade - Interesting Engineering

Posted in Preventative Medicine | Comments Off on Novel Dementia Vaccine Could Be the "Breakthrough" of the Decade – Interesting Engineering

Alzheimers Vaccine: Human Trials Expected To Commence In 2 Years – Medical Daily

Posted: January 9, 2020 at 9:49 am

Great hopes are being placed in a new vaccine that might be able to both prevent and cure dementia and Alzheimer's disease.

Developed by Prof. Nikolai Petrovsky, director of endocrinology at Flinders University in Adelaide, South Australia, after more than two decades of painstaking research and testing, this new vaccine's potential is so promising it's being hailed as the "breakthrough" of the decade in Alzheimer's research.

Petrovsky hopes human trials in the United States will start in the next 18 to 24 months. The vaccine was developed by Petrovsky but research is being led and funded by the Institute for Molecular Medicine (IMM) in California and the University of California in Oakland, which is the world's leading public research university system.

"With the vaccine, what we're doing is getting the immune system to make antibodies that can recognize those abnormal clumps of protein and will actually pull them out of the system and break them down," Petrovsky told ABC Australia. "It'll unblock the pipes and let the brain go back to normal."

The pipes Petrovsky refers to are the tens of billions of neurons in a healthy human brain. Neurons are specialized cells that process and transmit information throughout the body via electrical and chemical signals. They transmit messages between different parts of the brain, and from the brain to body organs.

Alzheimers disrupts the vital communication among neurons, causing loss of function and cell death. Early on, Alzheimers destroys neurons and their connections in parts of the brain involved in memory. It later corrupts areas in the cerebral cortex that are responsible for language, reasoning and social behavior. Many other areas of the brain will eventually be damaged. A person with advanced Alzheimers loses his or her ability to live and function independently. The disease is fatal within five to seven years.

"Currently, we believe Alzheimer's disease is caused by a build-up of abnormal clumps of protein in the brain," Petrovsky said. "It's like they gum up the system, a bit like when your pipes get blocked and they don't work so well.

He said the same thing happens in the brain with Alzheimer's. A person with the disease gets these build-ups of clumps of protein between the brain cells and they start to interfere with the communication between the brain cells.

Petrovsky is confident the human trials will turn out well.

"It's an exciting time to be starting the new decade -- hopefully this is the breakthrough of the next decade if we can get it to work in the human trials," he added. "It's an exciting juncture."

Petrovsky said the vaccine was designed to both be a preventative measure and a cure. He said that in animal models, the vaccine was used to prevent the development of memory loss by giving it before the animal starts to get these build-ups of proteins.

"But we can also show that even when we give it after the animals have proteins, we can actually get rid of the abnormal proteins. It's actually designed to be both a prophylactic and a therapeutic."

Increasing levels of protein from brain-derived neurotrophic factor (BDNF) gene expression could slow down the progression of Alzheimer's Disease. Pixabay

Continue reading here:
Alzheimers Vaccine: Human Trials Expected To Commence In 2 Years - Medical Daily

Posted in Preventative Medicine | Comments Off on Alzheimers Vaccine: Human Trials Expected To Commence In 2 Years – Medical Daily

How These Practitioners Can Help with New Year, New You Goals – Milwaukee Magazine

Posted: January 8, 2020 at 8:49 pm

This is a sponsored story

The start of a new year is the perfect time to prioritize self-care and set health and wellness goals, so make 2020 your happiest yet with a new, enhanced version of you. Use this guide to find the doctors, therapists and practitioners that can help you look and feel your best.

When diet and exercise just wont provide the results youre looking for, visit Skiin Anti-Aging Lounge. They offer the only procedure that builds muscle. EMSCULPT has been proven safe and effective by the most reputable scientific methods. The procedure induces strong muscle contractions with Hifem (high-intensity electromagnetic) technology not achievable through voluntary contractions. This builds muscle and creates a sculpted, toned physique. Other services like CoolSculpting and Exilis also help clients reshape their bodies through nonsurgical, noninvasive methods. Skiin is the first and only CoolSculpting advanced education center in the nation. Another first: Exilis is the first and only device to combine radio frequency and ultrasound to tighten skin through heating and cooling.

Your face is the first place to show signs of aging, but there is a way to take back those years. Dr. John Yousif has received several awards for his research in facial aging. He has been practicing plastic and cosmetic surgery for over 30 years and has even pioneered new techniques like the Gortex Midface Lift and the Hyoid Suspension Neck Lift. At both Sier Medi-Spa and Ascension in Mequon, he offers surgical and nonsurgical procedures to reverse the signs of aging. All of the types of facelifts offered are long-lasting and natural looking, leaving clients feeling like a younger version of themselves.

RELATED Your Guide to the New and Improved Wauwatosa Village

Aqua, under the direction of Dr. Christopher Hussussian, is a full-service salon, spa and med spa offering a wide range of services in a luxurious setting on Pewaukee Lake. Whether you are hoping to change the way you look or feel or both Aqua has a solution to enhance your skin and hair for both body and face. New services for the new year include hair restoration for both men and women using PRP (platelet-rich plasma) with biotin and a new weight-loss program using the HCG hormone. They also offer advanced laser hair removal, Clear Lift skin tightening, ThermiVa and CoolSculpting, a popular nonsurgical fat cell reduction with lasting results. A consultation can help you decide what services would work best to achieve a healthier, happier version of yourself.

Serving the Lake Country area, Dr. Tom Stamas is helping people put their best face forward, one smile at a time. He specializes in smile design, a full dental restoration and reconstruction for those suffering from tooth damage or loss, or for those looking to fix crooked, worn or yellowed teeth. During your personalized consultation, Stamas and his team will help you select which treatments will bring your smile to life. Dental treatments like bridges, dental implants, crowns and state-of-the-art diagnostic tools are all available to restore the health, function and appearance of your smile. Youll feel good about the natural-looking results, and your self-esteem will get a boost too.

What if you could use undesired fat from your belly to get rid of the bags under your eyes? Sounds too good to be true, right? Anew Skin and Wellness has a procedure that is done right in the office with long lasting results. The nano-fat transfer removes a small amount of fat with micro liposuction. That fat is harvested for re-injection to the appropriate areas of the face, neck, earlobes, hands and thighs. It can also be used to plump thin lips, smooth cellulite and scars and restore skin elasticity. The nano-fat transfer is safe, effective, economical and helps clients look their best. The in-office procedure provides long-lasting results because the bodys stem cells can turn the aging skin into new, rejuvenated skin. Its the natural way to tighten and smooth skin, allowing you to turn back the clock without a surgical face- or neck-lift.

RELATED An Insider's Guide to Oak Creek, Wisconsin

Dr. Arvind Ahuja has provided neurosurgical and endovascular care in southeastern Wisconsin for more than 20 years for brain, spine, artery and peripheral nerve conditions. Whether patients come to Neurosurgery and Endovascular Associates for neck and/or arm pain, back and/or leg pain or headache, the first step is always diagnostic testing to determine the cause of the pain, rather than just treating the symptoms. Often through treatments like medication, steroid injections, physical therapies and if need be surgery, patients achieve improved functioning and long-term relief. Ahujas specialized training in the nervous system is incredibly effective in treating spinal conditions, and his treatments give patients the opportunity to live a happier and morefunctional life.

Read the original post:
How These Practitioners Can Help with New Year, New You Goals - Milwaukee Magazine

Posted in HCG Diet | Comments Off on How These Practitioners Can Help with New Year, New You Goals – Milwaukee Magazine

Highs and Lows of Stem Cell Therapies: Off- The-Shelf Solutions – P&T Community

Posted: January 8, 2020 at 8:48 pm

NEW YORK, Jan. 7, 2020 /PRNewswire/ --

Report Includes: - An overview of recent advances in stem cell therapies and coverage of potential stem cells used for regenerative advanced therapies

Read the full report: https://www.reportlinker.com/p05835679/?utm_source=PRN

- Discussion on role of genomic and epigenomics manipulations in generating safe and effective treatment options - Identification of autologous and allogeneic cells and their usage in creating advanced therapy medical products (ATMPs) - Information on 3D cell culture and discussion on advances in gene editing and gene programming techniques such as CRIPSR/Cas9, TALEN, and ZINC fingers - Insights into commercial and regulatory landscape, and evaluation of challenges and opportunities for developing autologous and allogenic "off the shelf" solutions

Summary Stem cells are unique in their ability to divide and develop into different cell types that form tissues and organs in the body during development and growth.The stem cell's role is to repair impaired or depleted cells, tissues and organs in the body that are damaged by disease, injury, or normal wear and tear.

Stem cells are found in every organ, but are most abundant in bone marrow, where they help to restore the blood and immune system.

Stem cells may be derived from various sources, including - - Adult stem cells (ASCs): Derived from tissue after birth, these include bone marrow, brain, peripheral blood, skeletal muscle, skin, teeth, heat, gut, liver, ovarian epithelium and testis, as well as umbilical cord stem cells and blood. These cells are currently most widely used for cellbased therapies. Hematopoietic stem cells (HSCs), which are derived from bone marrow, can give rise to red blood cells, white blood cells and platelets, whereas mesenchymal stem cells (MSCs) are derived from the stroma and give rise to non-blood forming cells and tissues. - Human embryonic stem cells (hESCs): Derived from embryos, these include stems cell lines, aborted embryos or from miscarriages, unused in vitro fertilized embryos and cloned embryos. There are currently no clinically approved treatments for embryonic stem cells. - Inducible pluripotent stem cell (iPSCs): These are stem cells generated in the laboratory by reprogramming adult cells that have already differentiated into specific cells, such as liver cells. They are used either for research purposes (e.g., experimental medicine testing toxicity of new drugs) or are under research for potential future clinical use.

Read the full report: https://www.reportlinker.com/p05835679/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/highs-and-lows-of-stem-cell-therapies-off--the-shelf-solutions-300982411.html

SOURCE Reportlinker

Continued here:
Highs and Lows of Stem Cell Therapies: Off- The-Shelf Solutions - P&T Community

Posted in Stem Cell Treatments | Comments Off on Highs and Lows of Stem Cell Therapies: Off- The-Shelf Solutions – P&T Community

Promethera Announces Initiation of Phase 2b DHELIVER Study of HepaStem in Patients with Acute-on-Chronic Liver Failure (ACLF) – Business Wire

Posted: January 8, 2020 at 8:48 pm

MONT-SAINT-GUIBERT, Belgium & TOKYO--(BUSINESS WIRE)--Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the initiation of a Phase 2b clinical trial to evaluate the efficacy and safety of HepaStem, the companys liver-derived stem cell therapy candidate, in patients with Acute-on-Chronic Liver Failure (ACLF). The trial is open for recruitment and aims to include 363 patients with ACLF at 110 study sites across 22 countries in Europe. Topline results are expected to be released at a medical conference at the end of 2023.

The DHELIVER study (or HEP102) is a randomized, placebo-controlled, double-blinded, multicenter trial designed to assess the efficacy of HepaStem treatment on the overall survival proportion 90 days post-first infusion. Among the secondary trial objectives are additional efficacy assessments such as transplantation-free survival as well as continued evaluation of the treatments safety. Patients with Grade 1 or 2 ACLF will be eligible to screen for participation in the trial. The study will target enrolment of approximately 363 patients across two treatment arms: patients receiving two weekly intravenous infusions of HepaStem and patients receiving placebo.

We are developing HepaStem as a treatment for ACLF at a fast pace and we are determined to bring it to patients in need as soon as we can. As a potentially pivotal trial, the results obtained here may provide us with sufficient clinical data to file a new drug application, said Etienne Sokal, M.D., Ph.D., Founder and Group Chief Medical Officer of Promethera. Providing a treatment for a severe disease such as ACLF will not only help this patient population, but also greatly inform us in our efforts to develop treatments for other liver diseases, such as NASH.

ACLF is a severe, life threatening disease, with no current available treatments. The only option for patients is organ transplant, which is a major procedure and often not accessible. HepaStem has the potential to be the first real alternative to liver transplants in such a disease, and help ACLF patients in need, said John Tchelingerian, PhD, President and Chief Executive Officer of the Promethera Group. We are proud and excited to begin working towards the next milestone in the clinical development of HepaStem with the Phase 2b trial commencing and are looking forward to achieve the targets we set and bring HepaStem one step closer to an approved therapy.

In the previously concluded HEP101 trial, HepaStem has proven safe and tolerable in single or repeated injections in a total of 24 patients with Acute-on-Chronic Liver Failure (ACLF) or Acute Decompensation (AD) at high risk of developing ACLF. With one or two repeated doses up to 1.2 million cells per kilogram of body weight, no adverse events related to HepaStem occurred in the three-months follow-up period and no clinically significant changes were shown in platelet count, fibrinogen levels, and coagulation factors following HepaStem infusion. In addition to the positive safety profile, the study had shown preliminary signs of efficacy with improvement in three indicators of liver disease severity; Model for End Stage Liver Disease score (MELD), Child-Pugh score and bilirubin levels, 28 days and three months after treatment initiation.

About HepaStem

HepaStem consists of liver derived stem cells that are obtained from ethically donated healthy human organs and expanded in GMP culture conditions. Updated clinical data from the ongoing phase 2a study (HEP101) in patients with Acute-on-Chronic Liver Failure (ACLF) or Acute Decompensation (AD) at high risk of developing ACLF have been presented in an oral presentation at the Annual Meeting of the American Association for Study of Liver Diseases (AASLD) on November 10, 2019, in Boston, by Prometheras principal investigator Prof. F. Nevens, KULeuven, Belgium. The data set confirmed earlier findings presented at The International Liver Congress - ILC 2019 in April. A first clinical trial in NASH was initiated H1 2019.

About Promethera Biosciences SA (Promethera Group)

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera, HepaStem, H2stem, are all registered trademarks of the PROMETHERA group.

Contact Information:

See original here:
Promethera Announces Initiation of Phase 2b DHELIVER Study of HepaStem in Patients with Acute-on-Chronic Liver Failure (ACLF) - Business Wire

Posted in Stem Cell Treatments | Comments Off on Promethera Announces Initiation of Phase 2b DHELIVER Study of HepaStem in Patients with Acute-on-Chronic Liver Failure (ACLF) – Business Wire

Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 – ReportsPioneer

Posted: January 8, 2020 at 8:48 pm

Maximize Market Research published a Stem Cell Therapy Market report by keeping key players, end user, investors and all key stakeholders into consideration.

Stem Cell Therapy Market is expected to reach 202.77 billion by 2026 from XX billion in 2018 at CAGR of XX %.

The report will give in-depth analysis of market dynamics with competitive landscape, which will help user to understand their position in the market and ultimately will help to plan the strategies and implement the same as well.

The report includes PESTLE, Porters Five Forces, qualitative, and quantitative analysis that will help players to understand the market dynamics with current market size by region from supply side as well as from demand side. The regional analysis section unveils hidden market opportunities available in different regions and countries and in different segments.

Get PDF template of Stem Cell Therapy market report @ https://www.maximizemarketresearch.com/request-sample/522

Primary and secondary data collection methods are used to collect the data from reliable sources across the globe that include key players, end users, suppliers, members of associations across the countries and end user industries.Advanced research techniques and tools are used to prepare the report that make this report accurate and up-to-date with latest industry trends.

The global Stem Cell Therapy market is segmented by Treatment,Application,End Users and Geography. Each segment of the global Stem Cell Therapy market is thoroughly examined as per crucial factors such as market share, revenue, production, and CAGR. The report provides the statistical analysis where in market leaders followers and new entrants revenue, production, CAGR, M&A activities are presented in simple and format. Other aspects of the global Stem Cell Therapy market, including value chain, manufacturing cost, prices, gross margin, drivers, restraints, opportunities, Threats, and trends are also deeply analyzed.

Chiesi Farmaceutici S.P.A Are: Gamida Cell ReNeuron Group, plc Osiris Therapeutics, Inc. Stem Cells, Inc. Vericel Corporation. Mesoblast, Ltd.

DO INQUIRY BEFORE PURCHASING REPORT HERE @ https://www.maximizemarketresearch.com/inquiry-before-buying/522

Scope of the Global Stem Cell Therapy Market

Stem Cell Therapy Market, By Treatments:

Allogeneic Stem Cell TherapyAutologous Stem Cell Therapy

Stem Cell Therapy Market, By End Users:

HospitalsAmbulatory Surgical Centers

Stem Cell Therapy Market, By Application:

OncologyCentral Nervous System DiseasesEye DiseasesMusculoskeletal DiseasesWound & InjuriesMetabolic DisordersCardiovascular DisordersImmune System DisordersStem Cell Therapy Market, By Geography:

North AmericaEuropeAsia PacificMiddle East & AfricaLatin America

Market Forecasting

Besides short-term and long-term estimations related to the global Stem Cell Therapy market, repots has covered the demand, consumption, growth, and future course of market by region in the industry.

Customized Research

The report can be customized as per specific requirements of the clients.

Browse Full Report with Facts and Figures of Stem Cell Therapy Market Report @ https://www.maximizemarketresearch.com/market-report/stem-cell-therapy-market/522/

Table of Contents

Global Stem Cell Therapy Market

1. Preface1.1. Report Scope and Market Segmentation1.2. Research Highlights1.3. Research Objectives

2. Assumptions and Research Methodology2.1. Report Assumptions2.2. Abbreviations2.3. Research Methodology2.3.1. Secondary Research2.3.1.1. Secondary data2.3.1.2. Secondary Sources2.3.2. Primary Research2.3.2.1. Data from Primary Sources2.3.2.2. Breakdown of Primary Sources

Table of Contents Continuous..

Study Coverage: This is the first section of the report that includes highlights of market segmentation, years covered, study objectives, major manufactures of the global Stem Cell Therapy market, and product scope.

About Us:

Maximize Market Research provides syndicate as well as custom made business and market research on 6,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact Info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read more:
Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - ReportsPioneer

Posted in Stem Cell Treatments | Comments Off on Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 – ReportsPioneer

Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline…

Posted: January 8, 2020 at 8:48 pm

CARY, N.C. and BASEL, Switzerland and WAYNE, Pa., Jan. 8, 2020 /PRNewswire/ --Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, today announced that it has entered into a definitive agreement to acquire Onspira Therapeutics, a private drug development company similarly focused on therapeutics for rare pulmonary diseases. This acquisition expands Altavant's pipeline to include OSP-101, a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) with orphan drug designation from the U.S. Food and Drug Administration. OSP-101 is in preclinical development for the treatment of bronchiolitis obliterans syndrome (BOS), the leading non-infectious complication following lung transplantation and a major cause of death in these patients.

"Adding OSP-101 to our pipeline creates significant value for Altavant, while also furthering our mission to develop drugs for patients with very serious and rare lung diseases," said William T. Symonds, Pharm.D., Chief Executive Officer of Altavant. "Although a majority of lung transplant recipients develop this life-threatening condition, there are no treatments approved specifically for BOS and the current therapies have limited efficacy."

Joshua Diamond, MD, MSCE, Associate Medical Director of the Lung Transplant Program at the University of Pennsylvania, commented, "Despite advances in the management of patients following a lung transplant, BOS continues to be the leading cause of morbidity and mortality in these patients. We have a significant need for new therapies that will halt this progressive loss of lung function and improve the survival and quality of life for lung transplant patients."

"I am proud of the achievements of the entire Onspira Therapeutics team as we have progressed the OSP-101 program," said Brian Lortie, Chief Executive Officer of Onspira Therapeutics. He added, "We have been impressed by the talented and experienced professionals at Altavant, and we are confident that they are the right team to develop OSP-101 for the treatment of post-lung transplant BOS. This is an important program to bring forward for the benefit of lung transplant patients, and we believe Altavant is well-positioned to achieve this goal."

Under the terms of the agreement, Onspira's shareholders received an upfront payment and will receive additional payments upon the achievement of development, regulatory and commercial milestones. In addition, Onspira's shareholders will be eligible for royalties on net sales. This is the first acquisition conducted by a subsidiary of the the newly-formed Sumitovant Biopharma. The acquisition has closed and will have a minor effect on Sumitomo Dainippon Pharma's consolidated financial results for FY2019.

Hogan Lovells US LLP served as Altavant's legal counsel. Aquilo Partners, L.P. acted as the financial advisor to Onspira on the transaction and Duane Morris LLP served as Onspira's legal counsel.

About Bronchiolitis Obliterans SyndromeBronchiolitis obliterans syndrome (BOS) is a severe and progressive inflammatory condition resulting in airflow obstruction and loss of function in the lung. It is a form of chronic rejection that often follows lung transplant and hematopoietic stem cell transplantation and can also be caused by autoimmune diseases and by exposure to certain chemicals. BOS is the leading cause of morbidity and mortality in the pulmonary transplant population. According to the International Society for Heart and Lung Transplantation, an estimated 80 percent of patients who receive a lung transplant develop the condition within 10 years of their transplant. There are currently no approved drugs for the treatment of BOS.

About OSP-101OSP-101 is a novel, inhaled formulation of interleukin-1 receptor antagonist (IL-1Ra) in preclinical development for the treatment of bronchiolitis obliterans syndrome (BOS) in post-lung transplant patients. OSP-101 has received orphan drug designation from the FDA for the treatment of bronchiolitis obliterans.

About Altavant SciencesAltavant Sciences is a clinical-stage biopharmaceutical company focused on elevating patient-centric drug development in rare respiratory diseases with an initial focus on pulmonary arterial hypertension (PAH). Altavant's lead candidate for PAH, rodatristat ethyl, is a prodrug for rodatristat, a tryptophan hydroxylase (TPH) inhibitor that has achieved reductions in peripheral production of serotonin in healthy subjects, and may lower circulating serotonin levels in diseases where excessive production of the hormone has been implicated in their pathogenesis - including PAH, certain types of cancer, GI disorders, fibrosis and inflammation. Rodatristat ethyl is currently being evaluated in the ELEVATE1 Phase 2 study for patients with PAH. Altavant became a wholly owned subsidiary of Sumitovant Biopharma Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. in December 2019 through a strategic alliance between Sumitomo Dainippon Pharma and Roivant Sciences Ltd. (Headquarters: Basel, London, UK). For more information, please visit http://www.altavant.com.

About Onspira TherapeuticsOnspira Therapeutics was founded in 2017 with a focus on the development of life-changing medicines to bring hope to patients suffering from rare pulmonary diseases. OSP-101 is a novel compound being developed for the treatment of post-lung transplant bronchiolitis obliterans syndrome. More information regarding Onspira can be found at http://www.onspiratx.com.

About Sumitovant Biopharma Ltd.Sumitovant is a global biopharmaceutical company with offices in New York City and London. Sumitovant is a wholly owned subsidiary of Sumitomo Dainippon Pharma and the parent company of five biopharma subsidiaries: Myovant, Urovant, Enzyvant, Altavant and Spirovant. Sumitovant's pipeline is comprised of early- through late-stage investigational medicines across a range of disease areas targeting high unmet need. For further information about Sumitovant please visit https://www.sumitovant.com.

About Sumitomo Dainippon Pharma Co., Ltd.Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China and the European Union. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at https://www.ds-pharma.com.

Forward-Looking StatementsThis press release contains "forward-looking statements" concerning the development and commercialization of Altavant's products, the company's business development efforts and its expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Altavant undertakes no obligation to update any forward-looking statements for any reason.

SOURCE Altavant Sciences

http://www.altavant.com

Visit link:
Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline...

Posted in Stem Cell Treatments | Comments Off on Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline…

BLS Pharma Alleges Inovio’s Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender…

Posted: January 8, 2020 at 8:46 pm

SANTA ANA, Calif.--(BUSINESS WIRE)-- BLS Pharma, Inc. filed a complaint late last month against Genetronics, Inc. and Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Case No. 30-2019-01119045, for breaching a contract to supply a needle-free injection system that BLS Pharma was using to develop a drug-device combination (DDC) for testosterone replacement therapy.

Testosterone replacement therapy is a multi-billion-dollar market primarily used to treat male hypogonadism, a condition in which the body fails to produce enough testosterone. It is also a necessary treatment for transgender individuals transitioning and on lifetime hormone therapy from female to male.

Testosterone replacement therapy can make a significant difference for those in need of treatment. Our product would have allowed users to administer their treatments from the comfort of their own homes using a virtually painless needle-free system, said Mark Logomasini, President & CEO of BLS Pharma.

The shareholders of BLS Pharma previously developed the needleless injector technology, called Zetajet, and sold the intellectual property rights for it to Inovio and Genetronics, with the condition that Genetronics would execute a license and supply agreement to supply Zetajet units to BLS Pharma upon request. Under the agreement, BLS Pharma ordered 25,000 Zetajet units to prepare for its clinical trials on the DDC and was assured that the order was in process.

In September, BLS Pharma and Genetronics discussed the logistics of the syringe supply, and BLS Pharmas plan to offer the product for patients with hypogonadism and as a treatment for transgender males. The next business day, Inovio and Genetronics informed BLS Pharma they would not be supplying the syringes. This breach of contract eliminated BLS Pharmas ability to bring the DDC to market.

We are disappointed that we cannot offer this solution for male hypogonadism and to the transgender community, who have historically been marginalized by the medical and pharmaceutical community, stated Logomasini.

The testosterone treatment market is valued at 1.3 to 1.8 billion dollars annually. BLS Pharmas lost profits due to the breach of contract are estimated to be at least $72,900,000. All media inquiries should be directed to Jason Hartley of the Hartley LLP law firm at (619) 400-5822. For a copy of the complaint, email karen@fullkorrpress.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005928/en/

Go here to read the rest:
BLS Pharma Alleges Inovio's Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender...

Posted in Testosterone Replacement Therapy | Comments Off on BLS Pharma Alleges Inovio’s Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender…

Testosterone Replacement Therapy Market: Industry Growth Prospects & Trends Analysis by 2027 – Food & Beverage Herald

Posted: January 8, 2020 at 8:46 pm

Testosterone Replacement Therapy Market report presents the worldwide market size (Value, Production and Consumption), splits the breakdown (data status 2014-2019 and 5 Forces forecast 2020 to 2027), by manufacturers, region, type and application. This Testosterone Replacement Therapy market report profiles major topmost manufactures operating ( AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals) in terms of analyse various attributes such asProduction, Consumption, Revenue, Gross Margin, Cost, Gross, Market Share, CAGR, and Market Influencing Factors of the Testosterone Replacement Therapy industry in USA, EU, China, India, Japan and other regions Besides, the report also covers Testosterone Replacement Therapy market segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

GetFREE Sample PDF (including full TOC, Tables and Figures)of Testosterone Replacement TherapyMarket @

Research Methodology

WordWide Market Reports follows a comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

Primary Research (Trade Surveys and Experts Interviews)

Desk Research

Proprietor Data Analytics Model

In addition to this, WordWide Market Reports has access to a wide range of the regional andglobal reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the360 Degree Perspective i.e. from theSupply Side andDemand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, aTop-Down approach andBottom-Up approach is followed to arrive at ultimate research findings.

Key Target Audience of Testosterone Replacement Therapy Market: Manufacturers of Testosterone Replacement Therapy, Raw Material Suppliers, Market Research and Consulting Firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Testosterone Replacement Therapy.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Experts:https://www.worldwidemarketreports.com/speakanalyst/204548

There Are 11 Chapters To Deeply Display The Testosterone Replacement Therapy Market.

Chapter 1, is definition and segment of Testosterone Replacement Therapy; Chapter 2, is executive summary of Testosterone Replacement Therapy Market; Chapter 3, to explain the industry chain of Testosterone Replacement Therapy; Chapter 4, to show info and data comparison of Testosterone Replacement Therapy Players; Chapter 5, to show comparison of types; Chapter 6, to show comparison of applications; Chapter 7, to show comparison of regions and courtiers(or sub-regions); Chapter 8, to show competition and trade situation of Testosterone Replacement Therapy Market; Chapter 9, to forecast Testosterone Replacement Therapy market in the next years; Chapter 10, to show investment of Testosterone Replacement Therapy Market;

Key Questions Answered in the Testosterone Replacement Therapy Market Report:

What are the most recentAdvanced Technologies Adopted by Testosterone Replacement Therapy?

How are the recent trends affecting growth in the global Testosterone Replacement Therapy market?

What are theKey Strategies Used By Players And Service Providers that are expected to impact the growth of the Testosterone Replacement Therapy market?

What are theResources Available In Respective Regions that attract leading players in the Testosterone Replacement Therapy market?

What was theHistorical Value and what will be the forecast value of the Testosterone Replacement Therapy market?

Follow this link:
Testosterone Replacement Therapy Market: Industry Growth Prospects & Trends Analysis by 2027 - Food & Beverage Herald

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Replacement Therapy Market: Industry Growth Prospects & Trends Analysis by 2027 – Food & Beverage Herald

Testosterone Replacement Therapy Market Scope and Price Analysis of Top Manufacturers Profiles 2020-2027 – Primo Journal

Posted: January 8, 2020 at 8:46 pm

Global Testosterone Replacement Therapy Market Research Report will give its customers Full Analytical Research, that gives all in-out detailes about Key Players like company profile, product portfolio, capacity, price, cost and revenue for forecast period of 2020 2027. This Report gives full evaluation of Testosterone Replacement Therapy Market that containes Future trend, Current Growth Factors, attentive opinions, facts, historical data, and statistically supported and industry validated market data.

This Testosterone Replacement Therapy Market Research makes clear explanation on How or Why this market will take growth hike on mentioned period. A specific data of perticular characteristic such as Type, Size, Application, and end-user have been scanned in this research report. There are the basic segments included in segmentation analysis which are outcomes of SWOT analysis and PESTEL analysis.

Download Sample PDF of Testosterone Replacement Therapy Market Report

AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals are some of the major organizations dominating the global market.

Key players in the Testosterone Replacement Therapy market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All measurement shares, splits, and breakdowns have been resolute using secondary sources and verified primary sources. The Testosterone Replacement Therapy Market report begins with a basic overview of the industry lifecycle, definitions, classifications, applications, and industry chain structure and all these together will help leading players understand scope of the Market, what characteristics it offers and how it will fulfill customers requirements.

The report also makes some important proposals for a new project of Testosterone Replacement Therapy Market before evaluating its feasibility. Overall, the report covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Testosterone Replacement Therapy market. It offers facts related to the mergers, acquirement, partnerships, and joint venture activities widespread in the market.

This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Testosterone Replacement Therapy market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

What Testosterone Replacement Therapy Market report offers:

Regions Covered in This Report

The complete knowledge of Testosterone Replacement Therapy Market is based on the latest industry news, opportunities and trends. Testosterone Replacement Therapy Market research report offers a clear insight about the influential factors that are expected to transform the global market in the near future. Both top-down and bottom-up approaches have been used to estimate and validate the market size of Testosterone Replacement Therapy market, to estimate the size of various other dependent submarkets in the overall market.

Remarkable Attributes of Testosterone Replacement Therapy Market Report:

Customisation of the Report-In case of any queries or customisation requirements please connect with our Experts by Clicking Here who will ensure that your requirements are met.

See the article here:
Testosterone Replacement Therapy Market Scope and Price Analysis of Top Manufacturers Profiles 2020-2027 - Primo Journal

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Replacement Therapy Market Scope and Price Analysis of Top Manufacturers Profiles 2020-2027 – Primo Journal

Page 1,186«..1020..1,1851,1861,1871,188..1,2001,210..»